GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (NAS:KZR) » Definitions » Other Current Assets
中文

Kezar Life Sciences (Kezar Life Sciences) Other Current Assets

: $5.58 Mil (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Kezar Life Sciences's other current assets for the quarter that ended in Dec. 2023 was $5.58 Mil.

Kezar Life Sciences's quarterly other current assets declined from Jun. 2023 ($6.91 Mil) to Sep. 2023 ($5.31 Mil) but then increased from Sep. 2023 ($5.31 Mil) to Dec. 2023 ($5.58Mil).

Kezar Life Sciences's annual other current assets increased from Dec. 2021 ($3.30 Mil) to Dec. 2022 ($9.16 Mil) declined from Dec. 2022 ($9.16 Mil) to Dec. 2023 ($5.58 Mil).


Kezar Life Sciences Other Current Assets Historical Data

The historical data trend for Kezar Life Sciences's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Premium Member Only Premium Member Only Premium Member Only 2.93 4.36 3.30 9.16 5.58

Kezar Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Current Assets Take a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 7.56 6.91 5.31 5.58

Kezar Life Sciences Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Kezar Life Sciences Other Current Assets Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Kezar Life Sciences (Kezar Life Sciences) Business Description

Traded in Other Exchanges
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.
Executives
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Nicholas Michael Mordwinkin officer: Chief Business Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Wallace Courtney director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Micki Klearman director C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Equal Talent Investments Ltd 10 percent owner THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000
Noreen Henig officer: Chief Medical Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
John Franklin Fowler director, officer: CEO C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Christopher J. Kirk director, officer: President and CSO C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Belsky officer: Chief Financial Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Vassiliki Economides officer: SVP, Strategy & External Aff. C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Elizabeth Garner director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Gp, Llc 10 percent owner 100 HIGH STREET, SUITE 1105, BOSTON DC 02110
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111